About Ordaos: Ordaos is at the forefront of drug development, leveraging cutting-edge AI, machine learning, and computational biology to rapidly design mini-proteins with high therapeutic potential. The global drug discovery market is experiencing rapid growth, driven by the increasing complexity of diseases, rising demand for personalized medicine, and the need for more efficient drug development processes. Traditional drug discovery is expensive and time-consuming, with a high failure rate during clinical trials. The average cost to bring a new drug to market exceeds $2.6 billion, and the process can take over a decade. Ordaos currently has paid contracts with one of the top 3 pharma companies in the world for two feasibilty studies addressing two major therapeutic areas and is negotiating another paid feasibility contract with another one of the top 3 pharma companies to be executed by year end.

Artificial intelligence (AI) and machine learning have the potential to transform drug discovery by accelerating the identification of drug candidates, optimizing molecular designs, and predicting potential side effects before human trials. The AI-driven drug discovery market is projected to grow at a CAGR of 40% from 2023 to 2030, indicating substantial opportunities for companies that can successfully integrate AI into the drug development pipeline.

Ordaos is uniquely positioned to address this critical demand. Their proprietary AI platform enables faster, safer, and more effective drug candidates, drastically improving the traditional drug discovery process.

🗓️ Date: Wednesday, September 25th
⏰ Time: 3pm ET
📍 In-person: LMI, 7940 Jones Branch Dr, Tysons, VA 22102
💻 Virtual: Zoom (Link to be sent directly)